Table 1.
Demographic and clinical characteristics of study participants.
| Characteristics | No. (%)a, mean ± SD, or range |
|---|---|
| Age (years) | |
| Mean | 72.5 ± 15.6 |
| Range | 26–96 |
| < 65 | 3 (15.8) |
| ≥ 65 | 16 (84.2) |
| Gender | |
| Male | 14 (73.7) |
| Female | 5 (26.3) |
| Past medical history | |
| DM | 3 (15.8) |
| DED | 9 (47.4) |
| SS | 2 (10.5) |
| Atopic dermatitis | 1 (5.3) |
| Anti-glaucoma agents (preservative) | |
| Long-term medications | |
| Latanoprost (BAK) | 10 (38.5) |
| Carteolol (BAK) | 5 (19.2) |
| Brimonidine (purite) | 4 (15.4) |
| Dorzolamide/Timolol (BAK) | 4 (15.4) |
| Timolol (BAK) | 2 (7.7) |
| Pilocarpine (BAK) | 1 (3.8) |
| Last-added mediations | |
| Dorzolamide (BAK) | 2 (33.3) |
| Latanoprost (BAK) | 2 (33.3) |
| Carteolol (BAK) | 1 (16.7) |
| Dorzolamide/Timolol (BAK) | 1 (16.7) |
| Durations of anti-glaucoma agents usage | |
| Long-term medications | |
| ≤ 3 months | 4 (18.2) |
| > 3 months, ≤ 1 year | 8 (36.4) |
| > 1 year, ≤ 5 years | 6 (27.3) |
| > 5 years | 4 (18.2) |
| Last-added medications | |
| ≤ 1 month | 3 (50) |
| > 1 month | 3 (50) |
| Types of pseudodendritic lesions | |
| I | 1 (3.2) |
| II | 21 (67.7) |
| III | 2 (6.5) |
| IV | 2 (6.5) |
| V | 5 (16.1) |
| Locations of pseudodendritic lesions | |
| Upper | 0 |
| Center | 16 (51.6) |
| Lower | 15 (48.4) |
| Orientations of linear pseudodendritic lesions (type I and II lesions) | |
| Horizontal | 17 (77.3) |
| Curvilinear | 5 (22.7) |
DM diabetes mellitus, DED non-Sjogren dry eye disease, SS Sjogren syndrome.
aThe No. for age, gender and past medical history refers to the numbers of patients for each characteristic. The No. for anti-glaucoma agents refers to the numbers of episodes that each medication was used in. The No. for types and locations of pseudodendritic lesions, and orientations of linear pseudodendritic lesions refers to the numbers of events for each characteristic.